Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: A Prospective Comparative Study with a Follow up of 12 Months by Qorraj-Bytyqi, Hasime et al.
  
_______________________________________________________________________________________________________________________________ 
442                                                                                                                                                                                                https://www.id-press.eu/mjms/index 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2018 Mar 15; 6(3):442-446. 
https://doi.org/10.3889/oamjms.2018.142 
eISSN: 1857-9655 
Basic Science 
 
 
  
 
Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: 
A Prospective Comparative Study with a Follow up of 12 Months 
 
 
Hasime Qorraj-Bytyqi
1
, Rexhep Hoxha
1
, Shemsedin Sadiku
2
, Ismet H. Bajraktari
3
, Mentor Sopjani
4
, Kujtim Thaçi
5
, Shpetim 
Thaçi
4
, Elton Bahtiri
1,6*
 
 
1
Department of Pharmacology, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo; 
2
Clinic of Hematology, 
University Clinical Center of Kosovo, Prishtina, Kosovo; 
3
Clinic of Rheumatology, University Clinical Center of Kosovo, 
Prishtina, Kosovo;
 4
Department of Preclinical Studies, Faculty of Medicine, University of Prishtina, Kosovo; 
5
Institute of 
Biochemistry, University Clinical Center of Kosovo, Prishtina, Kosovo; 
6
Clinic of Endocrinology, University Clinical Center of 
Kosovo, Prishtina, Kosovo 
 
Citation: Qorraj-Bytyqi H, Hoxha R, Sadiku S, Bajraktari 
IH, Sopjani M, Thaçi K, Thaçi S, Bahtiri E. Proton Pump 
Inhibitors Intake and Iron and Vitamin B12 Status: A 
Prospective Comparative Study with a Follow up of 12 
Months. Open Access Maced J Med Sci. 2018 Mar 15; 
6(3):442-446. https://doi.org/10.3889/oamjms.2018.142 
Keywords: PPIs; Iron: Ferritin; Vitamin B12; 
Homocysteine 
*Correspondence: Elton Bahtiri. Department of 
Pharmacology, Faculty of Medicine, University of 
Prishtina, Prishtina, Kosovo. E-mail: elton.bahtiri@uni-
pr.edu 
Received: 05-Oct-2017; Revised: 20-Feb-2018; 
Accepted: 28-Feb-2018; Online first: 12-Mar-2018 
Copyright: © 2018 Hasime Qorraj-Bytyqi, Rexhep 
Hoxha, Shemsedin Sadiku, Ismet H. Bajraktari, Mentor 
Sopjani, Kujtim Thaçi, Shpetim Thaçi, Elton Bahtiri. This is 
an open-access article distributed under the terms of the 
Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC 4.0) 
Funding: This research was partly sponsored by a grant 
from the Ministry of Education, Science and Technology 
of Kosovo 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
 
 
Abstract  
BACKGROUND: Proton pump inhibitors (PPIs) represent the most widely prescribed antisecretory agents, but 
their prolonged use, may influence iron and vitamin B12 status, which could have important implications for 
clinical practice.  
AIM: We undertook this study aiming to investigate the association between PPIs use for 12 months and potential 
changes in iron and vitamin B12 status, as well as whether this potential association varies among four specific 
PPI drugs used in the study. 
METHODS: A total of 250 adult subjects were recruited into this study, of which 200 subjects were PPIs users 
while 50 subjects belonged to the control group. Serum iron, ferritin, vitamin B12, and homocysteine (Hcy) levels 
were measured before the start of the study and after 12 months. Mann - Whitney U test and Kruskal - Wallis test 
was used to compare the baseline characteristics of the study groups, while Wilcoxon test was used to analyse 
post - pre differences.  
RESULTS: Statistical analysis showed significant changes within PPIs group and specific PPIs subgroups 
between the two-time points in serum ferritin and vitamin B12 levels, respectively, while no significant changes in 
serum iron and homocysteine levels were shown. However, subsequent diagnosis of hypoferremia and 
hypovitaminosis B12 in the whole study sample at 12 months was established in only 3.8% and 2.9% of the 
subjects, respectively. 
CONCLUSION: PPIs use for 12 months did not result in clinically significant iron and/or vitamin B12 deficiency; 
thus, these findings argue routine screening under normal circumstances, although monitoring in elderly and 
malnourished may be of precious value. 
 
 
 
 
 
 
Introduction 
 
Proton pump inhibitors (PPIs) represent the 
most widely prescribed antisecretory agents [1] 
Prolonged PPIs use is not without consequences, 
however [1] [2]. Concerns have been raised about a 
possible association between prolonged PPIs use and 
increased risk for vitamin and mineral deficiencies [3] 
[4]. It has been suggested that their prolonged use 
may influence iron and vitamin B12 status due to 
potent suppression of gastric acid secretion by 
parietal cells, which could have important implications 
for clinical practice [5] [6]. Relatively few studies have 
specifically investigated the association between PPIs 
use and iron status and/or risk of anemia while what is 
known about the association between PPIs use and 
vitamin B12 deficiency is largely based on case -
reports or retrospective observational studies with 
considerable inconsistency in the findings [7] [8] [9] 
[10] [11] [12] [13] [14] [15] [16]. Moreover, they have 
failed to provide appropriate monitoring 
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recommendations in this regard [17]. Most of the 
previous studies provided only the data comparing 
“treatment” with “no treatment”, we therefore 
undertook this study aiming to prospectively 
investigate the association between PPIs use for 12 
months in new - users and potential changes in iron 
and vitamin B12 status, as well as whether this 
potential association varies among four specific PPI 
drugs used in the study. Also, the incidence of new-
onset hypoferremia and hypovitaminosis B12 and 
hyperhomocysteinemia (HHcy) during the study was 
assessed.  
 
 
Material and Methods 
 
The methodology of this open - labelled 
prospective study is described in greater detail 
elsewhere [18] [19]. Briefly, the study population 
consisted of subjects aged 18 to 65 years with a 
confirmed diagnosis of osteoarthritis of small joints of 
the hands and on chronic NSAIDs that indicated to 
initiate gastroprotective maintenance therapy with 
PPIs. Control group consisted of 50 matched healthy 
participants and with no gastrointestinal or other risk 
factors present for iron and vitamin B12 deficiency. 
The participants belonging to the groups under 
treatment with PPIs were contacted every 3 months 
by telephone to assess the adherence to PPIs and the 
potential adverse effects, while participants in the 
control group were contacted by telephone after 12 
months. 
Subjects were enrolled in the study only if 
they had serum iron, ferritin and vitamin B12 levels 
greater than lower reference limit provided by the lab 
(Table 1). Subjects were not included in the study if 
they were using parenteral and/or oral supplements of 
iron, vitamin B12 and folic acid, respectively, as well 
as any of the antisecretory agents (including PPIs) 
during preceding 12 months. Also, subjects with 
known hypersensitivity to any drug were excluded. 
Subjects were also excluded from the study if they 
were blood donors, were on vegetarian diet, were 
chronic alcohol abusers, were using concomitantly 
drugs (namely metformin, thyroid hormone 
supplements, antiepileptic drugs, anticoagulant drugs, 
oral contraceptives, glucocorticoids) and/or had 
diseases that may affect iron and vitamin B12 status 
(namely dementia, acute inflammatory diseases, 
malabsorption diseases, abnormal uterine, 
gastrointestinal or urinary bleeding, patients with 
atrophic gastritis or gastrectomy, thyroid diseases, 
renal diseases, cardiovascular diseases, neoplastic 
diseases including leukemias and lymphomas). 
Subjects were not included if they were pregnant, 
lactating or planning a pregnancy. To enhance the 
validity of our findings all the potential study 
participants were screened for exclusion mentioned 
above criteria. 
A total of 250 adult subjects were recruited 
into this study, of which 200 subjects were PPIs users 
of orally taken dosage forms of PPIs while 50 subjects 
belonged to the control group (PPIs nonusers). PPIs 
users were divided into four matched groups, each of 
them consisting of 50 subjects: patients on 
omeprazole therapy (20 mg/day), patients on 
esomeprazole therapy (20 mg/day), patients on 
lansoprazole therapy (30 mg/day), and patients on 
pantoprazole therapy (40 mg/day). 
 
Figure 1: Study design [18] 
 
All study participants provided written 
informed consent. Before the initiation of the study 
was obtained the approval of the study protocol from 
the local ethical committees of the University Clinical 
Center of Kosova and Faculty of Medicine, University 
of Prishtina. 
Fasting blood samples were collected from 
the antecubital vein at 8 AM, and were centrifuged 
within the first hour to separate the serum. The 
measurements of serum iron, ferritin, vitamin B12 and 
homocysteine levels were done before the start of the 
study (at baseline) and after 12 months. Serum iron, 
ferritin and homocysteine (enzymatic test) 
concentrations were measured simultaneously using 
automated analyser, COBAS Integra 400 Plus (Roche 
Diagnostics, Switzerland), while serum vitamin B12 
concentrations were measured by 
Electrochemiluminescence Immunoassay using 
Elecsys 2010 system (Roche Diagnostics, 
Switzerland). Hypoferremia was defined as serum 
levels of <10.6 μmol/l in male and < 6.6 μmol/l in 
female, hypoferritinemia was defined as serum levels 
of < 30 ng/ml in male and < 13 ng/ml in female, 
hypovitaminosis B12 was defined as serum levels of  
< 191 pg/ml, and hyperhomocysteinemia was defined 
as serum levels of >15 μmol/l.  
All the study results are expressed as the 
mean ± standard deviation and as percentages, as 
appropriate. The baseline continuous characteristics 
of the study groups were compared by using Mann -
Whitney U test and Kruskal-Wallis test, as 
appropriate, while baseline categorical characteristics 
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were compared by using the chi-square test. The 
Wilcoxon signed-rank test was used to analyse post -
pre differences in biochemical parameters. All 
statistical analyses were done with SPSS, version 20. 
A value of p < 0.05 was considered statistically 
significant. 
 
 
Results 
 
Out of a total of 250 participants that were 
initially recruited in the study, 209 participants 
completed 12 months of study. Thus only their data 
were analysed and presented here. The most 
common reasons for withdrawal from the study were 
non - compliance, changes in the place of residence 
and loss of follow - up, pregnancy and other personal 
reasons (Fig. 1). Most participants were female 
(74.6%), and the mean age at the beginning of the 
study was 50.59 ± 10.61 years. Mann - Whitney U test 
and Kruskal - Wallis test showed no significant 
differences in the baseline study characteristics 
between groups and subgroups (data not shown). 
Table 1: One-year changes in biochemical parameters 
according to study groups 
Biochemical 
parameters 
PPI users (n=209) p-value PPI non-users (n=42) p-value 
Pre-
treatment 
Post-
treatment 
Pre-treatment Post-treatment 
Homocysteine 
(5.5-15 µmol/l) 
14.22±3.3 14.5±4.3 0.32 14.7±4.3 13.8±3.2 0.08 
Vitamin B12 
(191-663 
pg/ml) 
433.6±122.5 393.5±139.4 <0.001 418.9±127.3 416.2±115.6 0.66 
Ferritin (ng/ml)a 135.2±111.2 94.1±76.2 <0.001 105.8±87.4 87.6±82.8 0.21 
Iron (μmol/l)b 17.6±5.23 16.9±5.4 0.049 19.0±4.9 19.6±4.9 0.14 
p-values according to Wilcoxon signed-rank test; a ♂: 30 - 400 ng/ml, ♀: 13 - 150 ng/ml; b ♂: 10.6 - 
28.3 μmol/l, ♀: 6.6 - 26.0 μmol/l. 
 
The results of the Wilcoxon signed - rank test 
summarised in Table 1 showed the statistically 
significant difference between the baseline and 12 
months’ serum ferritin and vitamin B12 levels within 
PPI group (p < 0.001 for both parameters). When 
specific PPI subgroups were analyzed (Table 2), the 
Wilcoxon signed - rank test showed that the most 
significant difference in mean serum ferritin levels was 
in pantoprazole group (p < 0.001), while the least, but 
still significant difference, was in omeprazole group (p 
= 0.01); as for serum vitamin B12 levels, the most 
significant difference was in lansoprazole group (p = 
0.004).  
Although the statistical analysis did not show 
any statistically significant difference in the mean iron 
serum levels between specific PPI subgroups (Table 
2), when all the study subjects under active treatment 
with PPIs were considered as a single group (Table 
1), the difference reached a borderline statistical 
significance (p = 0.049).  
No statistically significant difference in the 
mean homocysteine serum levels was noticed within 
PPI group and specific PPI subgroups; nevertheless, 
after 12 months, the incidence of the new - onset 
hyperhomocysteinemia in the whole study sample 
was 35.4 %, with sixty - six cases (39.5%) among 
PPIs users and eight cases (19.0%) among PPIs non-
users (39.5% vs 19.0%, p = 0.013).  
No statistically significant differences between 
PPIs users and non-users were noticed in the 
incidences of the new-onset of hypoferritinemia, 
hypoferremia and hypovitaminosis B12 (7.2% vs. 
9.5%, p = 0.610, 4.8% vs. 0%, p = 0.148 and 3.0% vs. 
2.4%, p = 0.832, respectively). 
Table 2: One - year changes in biochemical parameters 
according to study subgroups 
 
Biochemical 
parameter 
Pre-treatment Post-treatment p–value 
Omeprazole group 
(n=42) 
Homocysteine 14.3±3.9 14.5±3.0 0.48 
Vitamin B12 404.9±111.7 381.6±122.9 0.02 
Ferritin 133.1±101.1 99.5±87.9 0.01 
Iron  17.6±5.7 16.2±6.1 0.13 
Esomeprazole group 
(n=41) 
Homocysteine 14.1±3.0 14.5±2.3 0.19 
Vitamin B12 439.4±128.4 395.6±156.6 0.02 
Ferritin 121.0±105.5 91.2±67.8 0.001 
Iron 17.8±4.4 17.4±4.3 0.29 
Lansoprazole group 
(n=42) 
Homocysteine 14.9±3.4 15.1±2.7 0.79 
Vitamin B12 438.2±127.3 396.6±143.7 0.004 
Ferritin 138.7±114.7 93.3±76.7 0.001 
Iron 18.2±6.3 17.6±5.9 0.64 
Pantoprazole group 
(n=42) 
Homocysteine 13.5±2.6 13.9±7.2 0.81 
Vitamin B12 452.1±121.4 399.9±137.2 0.01 
Ferritin 147.6±124.3 92.4±73.4 <0.001 
Iron 16.9±4.6 16.8±5.2 0.30 
Control group  
(n=42) 
Homocysteine 14.7±4.3 13.8±3.2 0.08 
Vitamin B12 418.9±127.3 416.2±115.6 0.66 
Ferritin 105.8±87.4 87.6±82.8 0.21 
Iron 19.0±4.9 19.6±4.9 0.15 
p-values according to Wilcoxon signed-rank test; All the parameters are expressed as 
mean± standard deviation; 
 
It is noteworthy that no statistically significant 
difference was shown in the control group in any of 
the biochemical parameters of the study. 
 
 
Discussion 
 
The results of the current study indicate a 
significant association between PPIs use for 12 
months and reduction in iron body stores and vitamin 
B12 levels and higher prevalence of HHcy among PPI 
users. Our findings suggest that prolonged PPIs 
therapy affects iron and vitamin B12 status. 
Nevertheless, the subsequent diagnosis of 
hypoferremia and vitamin B12 deficiency at the end of 
the study was established in only 3.8% and 2.9% of 
the subjects, respectively, without significant 
differences between PPIs users and non - users.  
Early studies that noticed the association 
between clinical conditions associated with 
achlorhydria or hypochlorhydria and diminished 
intestinal iron absorption raised interest about the 
potential effect of prolonged PPIs therapy on iron 
status [7] [20]. Years later, through mutations on 
proton pumps on rats, Krieg et al. [21]
 
confirmed the 
necessity of gastric proton pump for iron absorption. 
Nevertheless, the number of studies that have 
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specifically investigated the association between 
prolonged PPIs use and iron status is relatively small. 
Among the first studies to suggest such an 
association is a case report of two anemic patients 
[12], in whom no response to oral substitutive therapy 
with iron was noted when the patients continued to 
take PPIs, while their iron status improved after PPIs 
withdrawal; this made the authors to attribute the 
nonresponsiveness to iron therapy to PPIs. In another 
study on patients with hereditary hemochromatosis 
that require frequent phlebotomies [22], administration 
of PPIs (omeprazole or lansoprazole) for 7 days 
resulted in significant reduction in the amount of blood 
removed per annum to maintain adequate iron body 
stores (ferritin levels of ∼50 µg/l). A retrospective 
cohort study of Sarzynski et al. [13] on adult 
outpatients who have been on PPI therapy for at least 
one year, demonstrated a significant reduction in 
hematologic indices compared to baseline values. 
Similarly, in a recent retrospective study of Shikata et 
al. [23] proved that PPIs use was associated with 
anaemia in cardiovascular outpatients, thus reporting 
a high frequency of anaemia among PPIs users 
compared to non-users (51% vs 19%, p < 0.001). 
The findings from this study indicate 
significant changes in iron body stores (serum ferritin 
levels) among PPIs and specific PPIs subgroups 
between the two time points, while no significant 
changes in serum iron levels (except for borderline 
significance when PPIs users as a single entity), and 
speak for pre-latent iron deficiency that is actually the 
initial phase in the pathogenesis of iron deficiency 
anemia.  
In recent years there has been growing 
interest in the relationship of PPIs prolonged use and 
vitamin B12 deficiency; however, there is still 
considerable uncertainty about providing monitoring 
recommendations [10] [24] [25]. The potential 
mechanisms behind the increased risk of vitamin B12 
deficiency in prolonged PPIs users are vitamin B12 
malabsorption and bacterial overgrowth in the gut [3] 
[4]. 
Marcuard et al. [8] were among the first to 
prove dose-dependent reduction of absorption of 
cyanocobalamin in healthy volunteers on short-term 
therapy with omeprazole for two weeks; nevertheless, 
an increased risk for vitamin B12 deficiency due to 
long-term use of PPIs was first reported by Termanini 
et al. [9] in a prospective study performed on patients 
with Zollinger-Ellison syndrome. In the last few years, 
much more information has become available about 
the association between long-term use of PPIs and 
vitamin B12 deficiency [10] [11] [24] [26]. More recent 
studies of Lam et al. [14] and Lewis et al. [25] have 
also indicated the presence of vitamin B12 deficiency 
in patients exposed to chronic PPIs.  
The findings from this study lend support to 
previous findings in the literature with data analysis 
indicating significant changes in vitamin B12 levels 
among PPIs users and specific PPIs subgroups at 12 
months as well as significantly higher in-study 
incidence of HHcy among PPIs users. Nevertheless, 
Hcy serum levels in PPIs users resulted in a slight but 
non-significant increase, that might seem 
controversial at first because Hcy reflects the 
functional status of vitamin B12, but it can be 
explained by the fact that higher levels of Hcy are 
more prevalent in lower levels of vitamin B12, and 
vitamin B12 deficiency was established in only 2.9 % 
of the subjects.  
On the other hand, we should mention that 
there are studies that do not support our findings of 
the association between long-term use of PPIs and 
vitamin B12 deficiency [7] [27] [28]. The main 
reason(s) for this inconsistency in findings is still not 
completely clear.  
We are aware that our study might have 
certain limitations. The first might be sample size as it 
was arbitrarily chosen. Another one is the inability to 
assess dietary intake of iron and vitamin B12. 
Unfortunately, we were unable to measure folic acid 
serum levels and methylmalonic acid serum levels, a 
specific marker of vitamin B12 status, which might 
have also influenced the results.  
In conclusion, in spite of the fact that 
significant changes on ferritin and vitamin B12 serum 
levels among PPIs users were shown, PPIs use for 12 
months did not result in clinically significant iron 
and/or vitamin B12 deficiency. These findings argue 
routine screening under normal circumstances; 
however, considerable attention must be paid when 
PPIs are prescribed in elderly and malnourished, 
where monitoring may be of precious value. 
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